Related Experiment Video
Updated: Feb 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Editorial: Statins and Liver Disease: Is it Time to Recommend Statins to Prevent Liver Disease Progression?
Jennifer C Price1, Phyllis C Tien1,2
1Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Abstract:
Evidence is emerging that statins may reduce liver-related adverse outcomes in individuals with chronic liver disease. In this issue of the American Journal of Gastroenterology, Kamal et al. found in their meta-analysis that statin use was associated with a reduced risk of fibrosis progression, decompensated cirrhosis, and mortality. These encouraging findings suggest beneficial liver effects of statins. However, the overall quality of the evidence is low because 9 of the 10 studies included in the meta-analysis were observational. More robust studies, including randomized trials and research on safety in patients with advanced liver disease, are needed before statins can be routinely recommended for prevention of liver-related morbidity and mortality.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures

